SANOFI US SERVICES INC. for SANOFI US SERVICES INC
What was lobbied
6 issue areas, each in the filer's own words, with who lobbied on it and where.
Budget/Appropriations BUD
Issues related to BARDA/Biodefense appropriations
Foreign entity interest: Sanofi US Services Inc is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| AMY L REDL | — |
| ELIZABETH STOWER | — |
Trade (domestic/foreign) TRD
Issues related to USMCA- United States- Mexico-Canada Agreement.
Foreign entity interest: Sanofi US Services Inc is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MARYANNE DOLBEARE DUNLAP | — |
| ELIZABETH STOWER | — |
Taxation/Internal Revenue Code TAX
Issues related to Tax Reform; issues related to H.R. 1973 "Vaccine Access Improvement Act of 2019" and issues related to S. 1654 Vaccine Access
Foreign entity interest: Sanofi US Services Inc is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JUAN MACHADO | — |
| AMY L REDL | — |
Copyright/Patent/Trademark CPT
Issues related to drug patents; and issues related to S. 1416 "Affordable Prescriptions for Patients Act of 2019".
Foreign entity interest: Sanofi US Services Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JUAN MACHADO | — |
Health Issues HCR
Issues related to the HHS Rebate rule; general issues related to drug pricing; issues related to cosmetic regulations; issues related to insulin pricing;issues related to s.102 "Prescription Drug Price Relief Act of 2019"; issues related to International Reference pricing; issues related to OTC Monograph Reform; issues related to prescription to over-the-counter switch; issues related to compulsory licensing; issues related to Drug Importation;issues related to H.R. 3 "Lower Drug Costs Now Act of 2019"; issues related to S. 2740 "Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019"; issues related to influenza vaccines; issues related to the Executive Order on Flu; and issues related to H.R. 19 "Lower Costs, More Cures Act of 2019" .
Foreign entity interest: Sanofi US Services Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MARYANNE DOLBEARE DUNLAP | — |
| JUAN MACHADO | — |
| KATIE OPPENHEIM | — |
| AMY L REDL | — |
| ELIZABETH STOWER | — |
Medicare/Medicaid MMM
Issues related to blended ASP authorized generics; issues related to Medicaid AMP CAP; issues related to S.99 "Medicare Drug Price Negotiation Act"; and issues related to Medicare Part D.
Foreign entity interest: Sanofi US Services Inc is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MARYANNE DOLBEARE DUNLAP | — |
| JUAN MACHADO | — |
| KATIE OPPENHEIM | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.